𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tu1236 Comparison of Techniques for Monitoring Infliximab Bioavailability and Immunogenicity in Crohn's Disease

✍ Scribed by Steenholdt, Casper; Svenson, Morten; Ainsworth, Mark A.; Thomsen, Ole.; Brynskov, Jorn; Bendtzen, Klaus

Book ID
122208058
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
183 KB
Volume
142
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Endoscopic monitoring of infliximab ther
Endoscopic monitoring of infliximab therapy in Crohn's disease
✍ Clas-GΓΆran af BjΓΆrkesten; Urpo Nieminen; Ulla Turunen; Perttu E. Arkkila; Taina πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 261 KB πŸ‘ 2 views

## Background: So far, infliximab (ifx) therapy for the treatment of crohn's disease (cd) has generally been guided by clinical symptoms. data on treatment response as ascertained by endoscopy in ifx therapy are scarce. the aims of this study were to measure the endoscopic response rate during ifx

Incidence and clinical significance of i
Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review
✍ Andrea Cassinotti; Simon Travis πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 167 KB

Background: Infliximab (IFX) is a chimeric (mouse/human) anti-TNF-alpha monoclonal antibody approved for the treatment of refractory luminal and fistulizing Crohn's disease (CD). It is a source of potential immunogenicity for humans, with the occurrence of anti-infliximab antibodies (ATIs), which ar

Individualized monitoring of drug bioava
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor Ξ± inhibitor infliximab
✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 151 KB πŸ‘ 2 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor Ξ± (anti‐TNFΞ±) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b